2no9
From Proteopedia
| Line 1: | Line 1: | ||
[[Image:2no9.gif|left|200px]] | [[Image:2no9.gif|left|200px]] | ||
| - | + | <!-- | |
| - | + | The line below this paragraph, containing "STRUCTURE_2no9", creates the "Structure Box" on the page. | |
| - | + | You may change the PDB parameter (which sets the PDB file loaded into the applet) | |
| - | + | or the SCENE parameter (which sets the initial scene displayed when the page is loaded), | |
| - | + | or leave the SCENE parameter empty for the default display. | |
| - | | | + | --> |
| - | | | + | {{STRUCTURE_2no9| PDB=2no9 | SCENE= }} |
| - | + | ||
| - | + | ||
| - | }} | + | |
'''The structure of deoxycytidine kinase complexed with troxacitabine and ADP.''' | '''The structure of deoxycytidine kinase complexed with troxacitabine and ADP.''' | ||
| Line 28: | Line 25: | ||
[[Category: Lavie, A.]] | [[Category: Lavie, A.]] | ||
[[Category: Sabini, E.]] | [[Category: Sabini, E.]] | ||
| - | [[Category: | + | [[Category: Anticancer]] |
| - | [[Category: | + | [[Category: Dck]] |
| - | [[Category: | + | [[Category: Enantiomer]] |
| - | [[Category: | + | [[Category: Human deoxycytidine kinase]] |
| - | [[Category: | + | [[Category: L-dc]] |
| - | [[Category: | + | [[Category: Troxacitabine]] |
| - | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun May 4 09:41:57 2008'' | |
| - | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | + | |
Revision as of 06:41, 4 May 2008
The structure of deoxycytidine kinase complexed with troxacitabine and ADP.
Overview
L-nucleoside analogs represent an important class of small molecules for treating both viral infections and cancers. These pro-drugs achieve pharmacological activity only after enzyme-catalyzed conversion to their tri-phosphorylated forms. Herein, we report the crystal structures of human deoxycytidine kinase (dCK) in complex with the L-nucleosides (-)-beta-2',3'-dideoxy-3'-thiacytidine (3TC)--an approved anti-human immunodeficiency virus (HIV) agent--and troxacitabine (TRO)--an experimental anti-neoplastic agent. The first step in activating these agents is catalyzed by dCK. Our studies reveal how dCK, which normally catalyzes phosphorylation of the natural D-nucleosides, can efficiently phosphorylate substrates with non-physiologic chirality. The capability of dCK to phosphorylate both D- and L-nucleosides and nucleoside analogs derives from structural properties of both the enzyme and the substrates themselves. First, the nucleoside-binding site tolerates substrates with different chiral configurations by maintaining virtually all of the protein-ligand interactions responsible for productive substrate positioning. Second, the pseudo-symmetry of nucleosides and nucleoside analogs in combination with their conformational flexibility allows the L- and D-enantiomeric forms to adopt similar shapes when bound to the enzyme. This is the first analysis of the structural basis for activation of L-nucleoside analogs, providing further impetus for discovery and clinical development of new agents in this molecular class.
About this Structure
2NO9 is a Single protein structure of sequence from Homo sapiens. Full crystallographic information is available from OCA.
Reference
Structural basis for activation of the therapeutic L-nucleoside analogs 3TC and troxacitabine by human deoxycytidine kinase., Sabini E, Hazra S, Konrad M, Burley SK, Lavie A, Nucleic Acids Res. 2007;35(1):186-92. Epub 2006 Dec 7. PMID:17158155 Page seeded by OCA on Sun May 4 09:41:57 2008
